Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units

Juan Figueroa-García, Víctor Granados-García, Ernesto Roldán-Valadez, David Rojano-Mejía, Jairo Enoc Cruz-Toledo, Silvia Palomo-Piñón

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. MATERIALS AND METHODS: A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, phar-macy records and unitary prices updated to 2019. RESULTS: From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associ-ated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 10 dollars (CI95% 8.3,12) in the group of ≥ 65 years. CONCLUSION: Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.

Original languageEnglish
Pages (from-to)188-195
Number of pages8
JournalSalud Publica de Mexico
Volume64
Issue number2
DOIs
StatePublished - 8 Apr 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units'. Together they form a unique fingerprint.

Cite this